BLR Bio, an innovative biotech company incubated at Rosalind Franklin University’s Helix 51, has unveiled promising results for its therapy for systemic sclerosis and lung fibrosis, offering hope for patients battling chronic disease. This achievement underscores the vital role of academic-industry collaborations in driving medical innovations. Kudos to BLR Bio and Rosalind Franklin University for their commitment to advancing healthcare solutions.
< BACK TO MAIN NEWS PAGE